Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Apr 7:2:29.
doi: 10.21037/tgh.2017.02.02. eCollection 2017.

The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study

Malinda Itchins  1 , Nick Pavlakis  1
Affiliations
Editorial

The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study

Malinda Itchins et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Nick Pavlakis is a consultant and has received honoraria from Roche, Eli Lily, Bayer; and has received grant funding from Bayer. Malinda Itchins has received honorarium from Pfizer, and has received travel support from Sanofi, Novartis, Amgen, BMS.

Figures

Figure 1
Figure 1
Kaplan-Meier plot of PFS. PFS, progression free survival; HR, hazard ratio.
Figure 2
Figure 2
Kaplan-Meier plot of OS. OS, overall survival; HR, hazard ratio.
See this image and copyright information in PMC

Comment on

References

    1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009;472:467-77. 10.1007/978-1-60327-492-0_23 - DOI - PubMed
    1. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol 2015;33:1760-9. 10.1200/JCO.2014.60.1799 - DOI - PubMed
    1. Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-8. 10.1200/JCO.2011.39.4585 - DOI - PubMed
    1. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:4438-44. 10.1200/JCO.2012.48.5805 - DOI - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. 10.1016/S0140-6736(10)61121-X - DOI - PubMed

LinkOut - more resources